Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by C10H12N2on Mar 21, 2023 9:15pm

161 Views

Post# 35352658

The CEO Is On Pace To Issue 5 BILLION shares in 5 Years.

Add it all up:

2:1 Reverse Split

100:1 Reverse Split

AGN Neuro - 33% Dilution

4:1 Forward Split

AGN.RT - 100% Dilution
____________________

^1.67 BILLION SHARES

Another 3 to 4 times dilution moving forward if any Phase 2 studies are conducted.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments